Hans van Houte
2022
In 2022, Hans van Houte earned a total compensation of $4.3M as Chief Financial Officer at Nurix Therapeutics, a 160% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $171,080 |
|---|---|
| Option Awards | $2,756,950 |
| Salary | $465,417 |
| Stock Awards | $899,990 |
| Other | $14,244 |
| Total | $4,307,781 |
van Houte received $2.8M in option awards, accounting for 64% of the total pay in 2022.
van Houte also received $171.1K in non-equity incentive plan, $465.4K in salary, $900K in stock awards and $14.2K in other compensation.
Rankings
In 2022, Hans van Houte's compensation ranked 788th out of 5,760 executives tracked by ExecPay. In other words, van Houte earned more than 86.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 788 out of 5,760 | 86th |
Division Manufacturing | 359 out of 3,136 | 89th |
Major group Chemicals And Allied Products | 121 out of 1,422 | 92nd |
Industry group Drugs | 108 out of 1,323 | 92nd |
Industry Pharmaceutical Preparations | 79 out of 969 | 92nd |
Source: SEC filing on March 24, 2023.
van Houte's colleagues
We found two more compensation records of executives who worked with Hans van Houte at Nurix Therapeutics in 2022.